Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Health Canada

- PMLiVE

OPEN Health discuss Global Community in Rare Disease

Annie Rankin how we can work smarter with healthcare professionals

OPEN Health

- PMLiVE

Revenue growth at Ipsen numbs pain of palovarotene calamity

French speciality drugmaker posted €2.58bn sales for the full-year

- PMLiVE

Chiesi launches new rare disease R&D division

New business unit will be based in Boston, US

Sanofi reception

Sanofi’s rare disease drug olipudase alfa scores in late-stage study

Met crucial endpoints across two clinical studies

- PMLiVE

Krystal Bio preps pivotal trials for rare skin disease gene therapy

Encouraging results for patients

- PMLiVE

Rare Diseases Day

More than other conditions, rare diseases require a human touch, but technology can provide a vital helping hand

Statistics and Infographics for Rare Disease Day

Rare Disease Day 2019

Today is #RareDiseaseDay and is an opportunity to highlight some truly unbelievable/frightening statistics around rare diseases.

Cuttsy + Cuttsy

- PMLiVE

Ipsen buys rare disease group Clementia in $1.3bn deal

Will acquire lead multiple rare disease candidate palovarotene

- PMLiVE

Encouraging data for GenSight’s blinding retinal disease gene therapy

Better results after April's setback

- PMLiVE

Ipsen hires general manager, Laura Hamill joins Gilead and Orchard expands leadership team

The latest industry movers

- PMLiVE

NICE clears Ipsen’s Cabometyx in first-line kidney cancer

Drug increased PFS by 2.6 months compared to Pfizer’s Sutent

- PMLiVE

Ipsen bolsters leadership team

Ivana Magovcevic-Liebisch and Régis Mulot join the biopharma

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links